/Regeneron%20Pharmaceuticals%2C%20Inc_%20website%20on%20phone-by%20madamF%20via%20Shutterstock.jpg)
Based in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company focused on discovering, developing, and commercializing innovative medicines. It is known for its robust pipeline and successful products such as EYLEA and Dupixent. With a market cap of $119.62 billion, Regeneron is a recognized leader in the biotechnology industry, dedicated to advancing science and delivering transformative therapies. The company is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1.
Ahead of the event, analysts expect REGN to report a profit of $8.89 per share, up 1.1% from $8.79 per share in the year-ago quarter. In the last four quarters, the company has surpassed Wall Street’s bottom-line estimates in three and missed on another occasion.